NCT01992289View on ClinicalTrials.gov

Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002

UnknownOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
X-linked Hypohidrotic Ectodermal Dysplasia
Interventions
DRUG

EDI200

Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002

Trial Locations (7)

20010

Children's National Medical Center, Washington D.C.

20157

"Azienda Ospedaliera-Polo Universitario Luigi Sacco", Milan

63110

Washington University School of Medicine, St Louis

75015

Hôpital Necker-Enfants Malades, Paris

91054

Universitätsklinikum Erlangen, Erlangen

94143

University of California, San Francisco, San Francisco

CF14 4XW

University Hospital of Wales, Cardiff

Sponsors
All Listed Sponsors
lead

Edimer Pharmaceuticals

INDUSTRY

NCT01992289 - Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002 | Biotech Hunter | Biotech Hunter